Nov 18, 2024 7:00am EST Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
Nov 14, 2024 7:00am EST Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Nov 07, 2024 4:01pm EST Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
Nov 04, 2024 7:00am EST Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
Oct 29, 2024 7:00am EDT Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
Oct 21, 2024 7:00am EDT Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
Sep 23, 2024 7:00am EDT Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
